However, inconsistent clinical responses and immune-related toxicities emphasize the need to elucidate the molecular drivers of immune escape and determinants of PD-1/PD-L1 inhibitor efficacy to ultimately reduce lung cancer mortality2. The gene discussed is CD274; the disease is lung carcinoma.